Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case.

The use of cost-effectiveness thresholds based on a country's income per capita has been criticized for not being relevant to decision making, in particular in middle-income countries such as South Africa. The recent South African HIV Investment Case produced an alternative cost-effectiveness t...

Full description

Bibliographic Details
Main Authors: Gesine Meyer-Rath, Craig van Rensburg, Bruce Larson, Lise Jamieson, Sydney Rosen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5658054?pdf=render
id doaj-4622749f97df47b29e1afc82abfcdbe4
record_format Article
spelling doaj-4622749f97df47b29e1afc82abfcdbe42020-11-25T01:46:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-011210e018649610.1371/journal.pone.0186496Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case.Gesine Meyer-RathCraig van RensburgBruce LarsonLise JamiesonSydney RosenThe use of cost-effectiveness thresholds based on a country's income per capita has been criticized for not being relevant to decision making, in particular in middle-income countries such as South Africa. The recent South African HIV Investment Case produced an alternative cost-effectiveness threshold for HIV prevention and treatment interventions based on estimates of life years saved and the country's committed HIV budget.We analysed the optimal mix of HIV interventions over a baseline of the current HIV programme under the committed HIV budget for 2016-2018. We calculated the incremental cost-effectiveness ratio (ICER) as cost per life-year saved (LYS) of 16 HIV prevention and treatment interventions over 20 years (2016-2035). We iteratively evaluated the most cost effective option (defined by an intervention and its coverage) over a rolling baseline to which the more cost effective options had already been added, thereby allowing for diminishing marginal returns to interventions. We constrained the list of interventions to those whose combined cost was affordable under the current HIV budget. Costs are presented from the government perspective, unadjusted for inflation and undiscounted, in 2016 USD.The current HIV budget of about $1.6 billion per year was sufficient to pay for the expansion of condom availability, medical male circumcision, universal treatment, and infant testing at 6 weeks to maximum coverage levels, while also implementing a social and behavior change mass media campaign with a message geared at increasing testing uptake and reducing the number of sexual partners. The combined ICER of this package of services was $547/ LYS. The ICER of the next intervention that was above the affordability threshold was $872/LYS.The results of the South African HIV Investment Case point to an HIV cost-effectiveness threshold based on affordability under the current budget of $547-872 per life year saved, a small fraction of the country's GDP per capita of about $6,000.http://europepmc.org/articles/PMC5658054?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Gesine Meyer-Rath
Craig van Rensburg
Bruce Larson
Lise Jamieson
Sydney Rosen
spellingShingle Gesine Meyer-Rath
Craig van Rensburg
Bruce Larson
Lise Jamieson
Sydney Rosen
Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case.
PLoS ONE
author_facet Gesine Meyer-Rath
Craig van Rensburg
Bruce Larson
Lise Jamieson
Sydney Rosen
author_sort Gesine Meyer-Rath
title Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case.
title_short Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case.
title_full Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case.
title_fullStr Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case.
title_full_unstemmed Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case.
title_sort revealed willingness-to-pay versus standard cost-effectiveness thresholds: evidence from the south african hiv investment case.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2017-01-01
description The use of cost-effectiveness thresholds based on a country's income per capita has been criticized for not being relevant to decision making, in particular in middle-income countries such as South Africa. The recent South African HIV Investment Case produced an alternative cost-effectiveness threshold for HIV prevention and treatment interventions based on estimates of life years saved and the country's committed HIV budget.We analysed the optimal mix of HIV interventions over a baseline of the current HIV programme under the committed HIV budget for 2016-2018. We calculated the incremental cost-effectiveness ratio (ICER) as cost per life-year saved (LYS) of 16 HIV prevention and treatment interventions over 20 years (2016-2035). We iteratively evaluated the most cost effective option (defined by an intervention and its coverage) over a rolling baseline to which the more cost effective options had already been added, thereby allowing for diminishing marginal returns to interventions. We constrained the list of interventions to those whose combined cost was affordable under the current HIV budget. Costs are presented from the government perspective, unadjusted for inflation and undiscounted, in 2016 USD.The current HIV budget of about $1.6 billion per year was sufficient to pay for the expansion of condom availability, medical male circumcision, universal treatment, and infant testing at 6 weeks to maximum coverage levels, while also implementing a social and behavior change mass media campaign with a message geared at increasing testing uptake and reducing the number of sexual partners. The combined ICER of this package of services was $547/ LYS. The ICER of the next intervention that was above the affordability threshold was $872/LYS.The results of the South African HIV Investment Case point to an HIV cost-effectiveness threshold based on affordability under the current budget of $547-872 per life year saved, a small fraction of the country's GDP per capita of about $6,000.
url http://europepmc.org/articles/PMC5658054?pdf=render
work_keys_str_mv AT gesinemeyerrath revealedwillingnesstopayversusstandardcosteffectivenessthresholdsevidencefromthesouthafricanhivinvestmentcase
AT craigvanrensburg revealedwillingnesstopayversusstandardcosteffectivenessthresholdsevidencefromthesouthafricanhivinvestmentcase
AT brucelarson revealedwillingnesstopayversusstandardcosteffectivenessthresholdsevidencefromthesouthafricanhivinvestmentcase
AT lisejamieson revealedwillingnesstopayversusstandardcosteffectivenessthresholdsevidencefromthesouthafricanhivinvestmentcase
AT sydneyrosen revealedwillingnesstopayversusstandardcosteffectivenessthresholdsevidencefromthesouthafricanhivinvestmentcase
_version_ 1725020927125618688